Concepts (270)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 32 | 2023 | 312 | 5.290 |
Why?
|
| Cognition Disorders | 16 | 2020 | 390 | 3.810 |
Why?
|
| Dementia | 20 | 2023 | 234 | 3.490 |
Why?
|
| Cognition | 23 | 2022 | 526 | 2.120 |
Why?
|
| Neuropsychological Tests | 19 | 2019 | 379 | 1.770 |
Why?
|
| Aged | 66 | 2023 | 9492 | 1.560 |
Why?
|
| Apolipoprotein E4 | 7 | 2020 | 58 | 1.500 |
Why?
|
| Apolipoproteins E | 7 | 2019 | 97 | 1.300 |
Why?
|
| Aging | 8 | 2022 | 881 | 1.280 |
Why?
|
| Humans | 87 | 2023 | 29123 | 1.200 |
Why?
|
| Residence Characteristics | 6 | 2022 | 181 | 1.190 |
Why?
|
| Female | 69 | 2023 | 18173 | 1.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 11 | 2022 | 1379 | 1.130 |
Why?
|
| Aged, 80 and over | 35 | 2023 | 3719 | 1.110 |
Why?
|
| Male | 53 | 2022 | 17815 | 0.930 |
Why?
|
| Cholesterol | 3 | 2019 | 229 | 0.920 |
Why?
|
| Diet | 5 | 2023 | 355 | 0.910 |
Why?
|
| Risk Factors | 24 | 2023 | 3537 | 0.870 |
Why?
|
| Cardiovascular Diseases | 8 | 2022 | 1017 | 0.860 |
Why?
|
| Women's Health | 8 | 2023 | 226 | 0.860 |
Why?
|
| Atherosclerosis | 3 | 2022 | 698 | 0.830 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2022 | 836 | 0.770 |
Why?
|
| Sleep | 2 | 2018 | 87 | 0.770 |
Why?
|
| Brain | 8 | 2021 | 930 | 0.730 |
Why?
|
| Inflammation | 3 | 2019 | 508 | 0.730 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 15 | 0.700 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 46 | 0.700 |
Why?
|
| Lipoproteins, LDL | 1 | 2019 | 77 | 0.670 |
Why?
|
| Delirium | 1 | 2018 | 13 | 0.650 |
Why?
|
| Environment | 1 | 2018 | 51 | 0.650 |
Why?
|
| Social Environment | 1 | 2018 | 75 | 0.640 |
Why?
|
| Lipids | 1 | 2019 | 210 | 0.620 |
Why?
|
| Membrane Transport Proteins | 2 | 2019 | 34 | 0.600 |
Why?
|
| Longevity | 3 | 2014 | 22 | 0.570 |
Why?
|
| Middle Aged | 24 | 2022 | 10834 | 0.530 |
Why?
|
| Utah | 11 | 2012 | 15 | 0.530 |
Why?
|
| Cross-Cultural Comparison | 1 | 2014 | 24 | 0.500 |
Why?
|
| Incidence | 11 | 2022 | 1119 | 0.500 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 37 | 0.470 |
Why?
|
| Dementia, Vascular | 5 | 2020 | 13 | 0.470 |
Why?
|
| Proportional Hazards Models | 9 | 2018 | 709 | 0.460 |
Why?
|
| Vitamin E | 3 | 2008 | 21 | 0.450 |
Why?
|
| Longitudinal Studies | 11 | 2018 | 721 | 0.450 |
Why?
|
| Postmenopause | 4 | 2019 | 397 | 0.450 |
Why?
|
| Cohort Studies | 10 | 2022 | 1688 | 0.440 |
Why?
|
| Overweight | 5 | 2022 | 256 | 0.430 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2008 | 71 | 0.420 |
Why?
|
| Weight Loss | 6 | 2022 | 413 | 0.400 |
Why?
|
| Prevalence | 8 | 2022 | 898 | 0.400 |
Why?
|
| Memory Disorders | 1 | 2012 | 61 | 0.400 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 196 | 0.400 |
Why?
|
| Life Style | 6 | 2022 | 364 | 0.390 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2022 | 48 | 0.360 |
Why?
|
| Obesity | 7 | 2022 | 1063 | 0.360 |
Why?
|
| Agricultural Workers' Diseases | 1 | 2010 | 86 | 0.350 |
Why?
|
| Sex Characteristics | 3 | 2020 | 167 | 0.350 |
Why?
|
| Genotype | 5 | 2012 | 735 | 0.330 |
Why?
|
| Follow-Up Studies | 11 | 2020 | 2109 | 0.330 |
Why?
|
| Risk | 5 | 2021 | 289 | 0.320 |
Why?
|
| Pesticides | 1 | 2010 | 189 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2021 | 1219 | 0.310 |
Why?
|
| Occupational Exposure | 1 | 2010 | 224 | 0.300 |
Why?
|
| Cerebrovascular Disorders | 2 | 2011 | 48 | 0.300 |
Why?
|
| Particulate Matter | 3 | 2022 | 30 | 0.290 |
Why?
|
| Dietary Supplements | 2 | 2008 | 170 | 0.290 |
Why?
|
| Odds Ratio | 3 | 2019 | 447 | 0.290 |
Why?
|
| Gene Frequency | 2 | 2010 | 225 | 0.280 |
Why?
|
| Mortality | 1 | 2007 | 109 | 0.280 |
Why?
|
| United States | 8 | 2022 | 3632 | 0.270 |
Why?
|
| Genome-Wide Association Study | 3 | 2022 | 543 | 0.270 |
Why?
|
| Stroke | 2 | 2015 | 548 | 0.260 |
Why?
|
| Memory | 2 | 2018 | 187 | 0.250 |
Why?
|
| Proxy | 1 | 2004 | 9 | 0.250 |
Why?
|
| Antihypertensive Agents | 5 | 2022 | 342 | 0.240 |
Why?
|
| Hormone Replacement Therapy | 3 | 2022 | 86 | 0.240 |
Why?
|
| Time Factors | 4 | 2020 | 2001 | 0.230 |
Why?
|
| Hypertension | 3 | 2022 | 910 | 0.230 |
Why?
|
| Factor Analysis, Statistical | 2 | 2013 | 70 | 0.220 |
Why?
|
| Diet, Mediterranean | 1 | 2022 | 23 | 0.210 |
Why?
|
| Vitamin B Complex | 1 | 2022 | 2 | 0.210 |
Why?
|
| Testosterone | 1 | 2022 | 47 | 0.210 |
Why?
|
| Risk Assessment | 4 | 2018 | 1306 | 0.210 |
Why?
|
| Air Pollution | 1 | 2021 | 17 | 0.210 |
Why?
|
| Air Pollutants | 1 | 2021 | 20 | 0.210 |
Why?
|
| Health Status | 2 | 2019 | 368 | 0.210 |
Why?
|
| Gait | 1 | 2022 | 115 | 0.210 |
Why?
|
| Mental Disorders | 2 | 2013 | 103 | 0.200 |
Why?
|
| Mass Screening | 1 | 2003 | 223 | 0.200 |
Why?
|
| Prospective Studies | 8 | 2022 | 2021 | 0.200 |
Why?
|
| Body Weight | 2 | 2020 | 290 | 0.200 |
Why?
|
| Disease Progression | 3 | 2013 | 572 | 0.200 |
Why?
|
| Age of Onset | 2 | 2018 | 95 | 0.200 |
Why?
|
| C-Reactive Protein | 2 | 2019 | 232 | 0.200 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2020 | 52 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 368 | 0.180 |
Why?
|
| Body Size | 1 | 2020 | 31 | 0.180 |
Why?
|
| Anthropometry | 1 | 2020 | 82 | 0.180 |
Why?
|
| Apolipoprotein C-I | 1 | 2019 | 4 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2019 | 13 | 0.170 |
Why?
|
| Problem Solving | 1 | 2018 | 28 | 0.170 |
Why?
|
| Gender Identity | 1 | 2018 | 18 | 0.170 |
Why?
|
| Forecasting | 1 | 2019 | 133 | 0.160 |
Why?
|
| Editorial Policies | 1 | 2018 | 12 | 0.160 |
Why?
|
| Blood Pressure | 2 | 2022 | 806 | 0.160 |
Why?
|
| Cost of Illness | 1 | 2018 | 63 | 0.160 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 355 | 0.160 |
Why?
|
| Ascorbic Acid | 2 | 2008 | 21 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2010 | 186 | 0.150 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 101 | 0.150 |
Why?
|
| Logistic Models | 1 | 2019 | 727 | 0.150 |
Why?
|
| Diet Surveys | 1 | 2017 | 56 | 0.150 |
Why?
|
| Databases, Factual | 1 | 2018 | 332 | 0.150 |
Why?
|
| Antioxidants | 2 | 2008 | 114 | 0.150 |
Why?
|
| Continental Population Groups | 1 | 2018 | 221 | 0.140 |
Why?
|
| Anorexia | 1 | 2016 | 4 | 0.140 |
Why?
|
| Decision Making | 1 | 2018 | 180 | 0.140 |
Why?
|
| Age Factors | 4 | 2015 | 1108 | 0.140 |
Why?
|
| Trace Elements | 1 | 2015 | 7 | 0.140 |
Why?
|
| Metals, Heavy | 1 | 2015 | 7 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2016 | 36 | 0.140 |
Why?
|
| Ethnic Groups | 1 | 2018 | 440 | 0.130 |
Why?
|
| Translations | 1 | 2014 | 1 | 0.130 |
Why?
|
| Russia | 1 | 2014 | 2 | 0.130 |
Why?
|
| Phenotype | 2 | 2013 | 629 | 0.130 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2014 | 10 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2015 | 122 | 0.120 |
Why?
|
| Language | 1 | 2013 | 44 | 0.120 |
Why?
|
| Executive Function | 1 | 2013 | 54 | 0.120 |
Why?
|
| Atrial Fibrillation | 2 | 2015 | 314 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2015 | 1079 | 0.110 |
Why?
|
| Questionnaires | 2 | 2010 | 3 | 0.110 |
Why?
|
| Attention | 1 | 2013 | 83 | 0.110 |
Why?
|
| Registries | 1 | 2014 | 278 | 0.110 |
Why?
|
| Patient Selection | 1 | 2014 | 257 | 0.110 |
Why?
|
| Depression | 3 | 2022 | 382 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2013 | 163 | 0.100 |
Why?
|
| Menopause | 1 | 2012 | 86 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 726 | 0.100 |
Why?
|
| Exercise | 3 | 2023 | 592 | 0.100 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2012 | 182 | 0.100 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 1362 | 0.100 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2011 | 7 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2010 | 440 | 0.090 |
Why?
|
| Time | 1 | 2010 | 21 | 0.090 |
Why?
|
| Adult | 5 | 2023 | 8426 | 0.090 |
Why?
|
| Environmental Exposure | 2 | 2021 | 87 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 67 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 13 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2010 | 90 | 0.090 |
Why?
|
| Sex Factors | 2 | 2015 | 631 | 0.090 |
Why?
|
| Genetics | 1 | 2009 | 4 | 0.090 |
Why?
|
| Toxicology | 1 | 2009 | 6 | 0.090 |
Why?
|
| Neurotoxins | 1 | 2009 | 16 | 0.090 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2009 | 17 | 0.090 |
Why?
|
| Behavior | 1 | 2009 | 29 | 0.090 |
Why?
|
| Actins | 1 | 2009 | 52 | 0.090 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2009 | 71 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2008 | 59 | 0.080 |
Why?
|
| Age Distribution | 2 | 2007 | 198 | 0.080 |
Why?
|
| Mental Processes | 1 | 2008 | 17 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2010 | 251 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2016 | 859 | 0.080 |
Why?
|
| Confidence Intervals | 2 | 2005 | 140 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2007 | 20 | 0.080 |
Why?
|
| Carotenoids | 1 | 2007 | 9 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 126 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2013 | 92 | 0.070 |
Why?
|
| Causality | 1 | 2006 | 37 | 0.070 |
Why?
|
| Religion | 1 | 2006 | 30 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2006 | 106 | 0.070 |
Why?
|
| Genetics, Population | 1 | 2005 | 30 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2006 | 240 | 0.060 |
Why?
|
| ROC Curve | 1 | 2003 | 149 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 863 | 0.060 |
Why?
|
| Blood Proteins | 1 | 2023 | 18 | 0.060 |
Why?
|
| Anxiety | 2 | 2016 | 159 | 0.060 |
Why?
|
| Autopsy | 2 | 2015 | 37 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 1 | 2023 | 45 | 0.060 |
Why?
|
| Histamine H2 Antagonists | 1 | 2002 | 2 | 0.060 |
Why?
|
| tau Proteins | 1 | 2023 | 38 | 0.060 |
Why?
|
| Antigens, Neoplasm | 1 | 2023 | 44 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 637 | 0.050 |
Why?
|
| Life Change Events | 1 | 2022 | 21 | 0.050 |
Why?
|
| Acceleration | 1 | 2022 | 60 | 0.050 |
Why?
|
| Vitamin B 12 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 92 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 532 | 0.050 |
Why?
|
| Rest | 1 | 2022 | 49 | 0.050 |
Why?
|
| Folic Acid | 1 | 2022 | 12 | 0.050 |
Why?
|
| Loneliness | 1 | 2022 | 7 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 65 | 0.050 |
Why?
|
| Dioxygenases | 1 | 2021 | 1 | 0.050 |
Why?
|
| Public Health | 1 | 2022 | 73 | 0.050 |
Why?
|
| Cause of Death | 2 | 2018 | 220 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 103 | 0.050 |
Why?
|
| Estradiol | 1 | 2022 | 118 | 0.050 |
Why?
|
| Repressor Proteins | 1 | 2021 | 53 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 787 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 142 | 0.050 |
Why?
|
| Cytokines | 1 | 2022 | 243 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2022 | 182 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 172 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2022 | 208 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3101 | 0.050 |
Why?
|
| Calcium | 1 | 2022 | 297 | 0.050 |
Why?
|
| Algorithms | 1 | 2003 | 462 | 0.050 |
Why?
|
| Quality of Life | 1 | 2006 | 816 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2020 | 43 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 116 | 0.050 |
Why?
|
| Thinness | 1 | 2020 | 31 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2020 | 89 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 165 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2020 | 95 | 0.040 |
Why?
|
| Adiposity | 1 | 2020 | 191 | 0.040 |
Why?
|
| Weight Gain | 1 | 2020 | 108 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 196 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2018 | 8 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2018 | 14 | 0.040 |
Why?
|
| Voluntary Health Agencies | 1 | 2018 | 1 | 0.040 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2018 | 7 | 0.040 |
Why?
|
| China | 1 | 2018 | 44 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2018 | 89 | 0.040 |
Why?
|
| Asian Americans | 1 | 2018 | 98 | 0.040 |
Why?
|
| Adiponectin | 1 | 2018 | 103 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2018 | 165 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2018 | 92 | 0.040 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2018 | 157 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2018 | 225 | 0.040 |
Why?
|
| Triglycerides | 1 | 2018 | 214 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 200 | 0.040 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2017 | 89 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 95 | 0.040 |
Why?
|
| Guilt | 1 | 2016 | 1 | 0.040 |
Why?
|
| Research Design | 1 | 2018 | 286 | 0.040 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2017 | 125 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2020 | 865 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2018 | 153 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2015 | 169 | 0.030 |
Why?
|
| Survival Rate | 2 | 2007 | 795 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1362 | 0.030 |
Why?
|
| Comorbidity | 2 | 2007 | 540 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2018 | 1131 | 0.030 |
Why?
|
| Animals | 2 | 2018 | 7300 | 0.030 |
Why?
|
| Irritable Mood | 1 | 2012 | 3 | 0.030 |
Why?
|
| Hispanic Americans | 1 | 2018 | 904 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2012 | 182 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2011 | 9 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2011 | 25 | 0.020 |
Why?
|
| African Americans | 1 | 2018 | 1373 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2010 | 34 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2010 | 61 | 0.020 |
Why?
|
| Phylogeny | 1 | 2009 | 58 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2006 | 3112 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2007 | 19 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 274 | 0.020 |
Why?
|
| Food Habits | 1 | 2007 | 1 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 426 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 273 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2007 | 33 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 100 | 0.020 |
Why?
|
| Educational Status | 1 | 2007 | 164 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2007 | 211 | 0.020 |
Why?
|
| Hearing | 1 | 2006 | 11 | 0.020 |
Why?
|
| Vision, Ocular | 1 | 2006 | 30 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 980 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 413 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 2402 | 0.010 |
Why?
|
| Aspirin | 1 | 2002 | 62 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 293 | 0.010 |
Why?
|